batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Triple meeting 2023 – no monotherapy activity for Repare 16 October 2023 Two BCL-2 inhibitors feature in phase 3 starts 13 October 2023 Merck kicks off its first TROP2 phase 3 11 October 2023 Merck hits another Keynote in perioperative lung 10 October 2023 Roche keeps expanding its SERD phase 3 programme 5 October 2023 The second phase 3 Claudin18.2 asset belongs to Transcenta 4 October 2023 The end of Exkivity is another win for Rybrevant 3 October 2023 Lilly makes its Point in radiopharmaceuticals 3 October 2023 Load More